Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Fundamental Analysis

USA - NASDAQ:ACXP - US00510M2035 - Common Stock

4 USD
-0.15 (-3.61%)
Last: 9/25/2025, 2:26:39 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ACXP. ACXP was compared to 538 industry peers in the Biotechnology industry. While ACXP seems to be doing ok healthwise, there are quite some concerns on its profitability. ACXP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACXP has reported negative net income.
ACXP had a negative operating cash flow in the past year.
In the past 5 years ACXP always reported negative net income.
In the past 5 years ACXP always reported negative operating cash flow.
ACXP Yearly Net Income VS EBIT VS OCF VS FCFACXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

ACXP has a worse Return On Assets (-162.38%) than 87.36% of its industry peers.
The Return On Equity of ACXP (-280.37%) is worse than 70.26% of its industry peers.
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROIC N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ACXP Yearly ROA, ROE, ROICACXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

ACXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACXP Yearly Profit, Operating, Gross MarginsACXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ACXP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACXP has been increased compared to 5 years ago.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACXP Yearly Shares OutstandingACXP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
ACXP Yearly Total Debt VS Total AssetsACXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ACXP has an Altman-Z score of -19.46. This is a bad value and indicates that ACXP is not financially healthy and even has some risk of bankruptcy.
ACXP's Altman-Z score of -19.46 is on the low side compared to the rest of the industry. ACXP is outperformed by 84.39% of its industry peers.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.46
ROIC/WACCN/A
WACCN/A
ACXP Yearly LT Debt VS Equity VS FCFACXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 2.38 indicates that ACXP has no problem at all paying its short term obligations.
With a Current ratio value of 2.38, ACXP is not doing good in the industry: 70.26% of the companies in the same industry are doing better.
A Quick Ratio of 2.38 indicates that ACXP has no problem at all paying its short term obligations.
With a Quick ratio value of 2.38, ACXP is not doing good in the industry: 67.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
ACXP Yearly Current Assets VS Current LiabilitesACXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

ACXP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -75.53%.
EPS 1Y (TTM)-75.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.34%
EPS Next 2Y9.02%
EPS Next 3Y18.72%
EPS Next 5Y9.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACXP Yearly Revenue VS EstimatesACXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 50M 100M 150M
ACXP Yearly EPS VS EstimatesACXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACXP Price Earnings VS Forward Price EarningsACXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACXP Per share dataACXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ACXP's earnings are expected to grow with 18.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.02%
EPS Next 3Y18.72%

More info and screens

0

5. Dividend

5.1 Amount

ACXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (9/25/2025, 2:26:39 PM)

4

-0.15 (-3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11
Inst Owners15.43%
Inst Owner Change-25.38%
Ins Owners10.95%
Ins Owner Change0%
Market Cap6.32M
Analysts82.22
Price Target62.93 (1473.25%)
Short Float %N/A
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.18%
Min EPS beat(2)18.25%
Max EPS beat(2)28.1%
EPS beat(4)4
Avg EPS beat(4)18.97%
Min EPS beat(4)12.85%
Max EPS beat(4)28.1%
EPS beat(8)5
Avg EPS beat(8)2.37%
EPS beat(12)7
Avg EPS beat(12)3.64%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)982.93%
PT rev (3m)982.93%
EPS NQ rev (1m)50.94%
EPS NQ rev (3m)-504.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-1318.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-10.69
EYN/A
EPS(NY)-9.8
Fwd EYN/A
FCF(TTM)-5.17
FCFYN/A
OCF(TTM)-5.17
OCFYN/A
SpS0
BVpS2.26
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -19.46
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.65%
EPS Next Y11.34%
EPS Next 2Y9.02%
EPS Next 3Y18.72%
EPS Next 5Y9.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.64%
EBIT Next 3Y3.95%
EBIT Next 5YN/A
FCF growth 1Y-13.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.68%
OCF growth 3YN/A
OCF growth 5YN/A